Zerion Pharma A/S - CVR: 40169229

2022, DKK

29.06.2023

Bruttoresultat

-10.913'

Primær drift

-20.892'

Årets resultat

-18.857'

Aktiver

12.423'

Kortfristede aktiver

9.478'

Egenkapital

-9.958'

Afkastningsgrad

-168 %

Soliditetsgrad

-80 %

Likviditetsgrad

214 %

Resultat

29.06.2023

Årsrapport	2022 29.06.2023	2021 07.06.2022	2020 11.05.2021	2019 05.05.2020
Nettoomsætning	3.273.327	1.932.775
Bruttoresultat	-10.912.651	-6.714.675	0	-1.068.242
Resultat af primær drift	-20.891.826	-13.179.938	-3.740.154	-1.346.954
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0
Finansielle indtægter	3.832	5.276	0	0
Finansieringsomkostninger	0	0	-271.269	0
Andre finansielle omkostninger	-1.241.102	-571.127	0	0
Resultat før skat	-22.129.096	-13.745.789	-4.011.423	0
Resultat	-18.857.318	-11.134.049	-3.477.649	-1.050.624
Forslag til udbytte	0	0	0	0

Aktiver

29.06.2023

Årsrapport	2022 29.06.2023	2021 07.06.2022	2020 11.05.2021	2019 05.05.2020
Kortfristede varebeholdninger	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	5.373.907	4.938.666	2.248.514	455.240
Likvider	4.103.621	6.644.491	3.948.613	579.287
Kortfristede aktiver	9.477.528	11.583.157	6.197.127	1.034.527
Immaterielle aktiver og goodwill	0	0	0	0
Finansielle anlægsaktiver	0	0	0	0
Materielle aktiver	2.945.727	2.114.467	802.626	0
Langfristede aktiver	2.945.727	2.114.467	802.626	0
Aktiver	12.423.255	13.697.624	6.999.753	1.034.527

Aktiver

29.06.2023

Passiver

29.06.2023

Årsrapport	2022 29.06.2023	2021 07.06.2022	2020 11.05.2021	2019 05.05.2020
Forslag til udbytte	0	0	0	0
Egenkapital	-9.958.078	-866.830	-1.029.105	31.476
Hensatte forpligtelser	0	0	0	0
Langfristet gæld til banker	0	0	0	0
Anden langfristet gæld	0	0	6.374.078	0
Leverandører af varer og tjenesteydelser	1.987.244	2.366.480	760.479	391.246
Kortfristede forpligtelser	4.432.315	3.984.981	1.654.780	1.003.051
Gældsforpligtelser	22.381.333	14.564.454	8.028.858	1.003.051
Forpligtelser	22.381.333	14.564.454	8.028.858	1.003.051
Passiver	12.423.255	13.697.624	6.999.753	1.034.527

Passiver

29.06.2023

Nøgletal

29.06.2023

Årsrapport	2022 29.06.2023	2021 07.06.2022	2020 11.05.2021	2019 05.05.2020
Afkastningsgrad	-168,2 %	-96,2 %	-53,4 %	-130,2 %
Dækningsgrad	-333,4 %	-347,4 %	Na.	Na.
Resultatgrad	-576,1 %	-576,1 %	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.
Egenkapitals-forretning	189,4 %	1.284,5 %	337,9 %	-3.337,9 %
Payout-ratio	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.	-1.378,8 %	Na.
Soliditestgrad	-80,2 %	-6,3 %	-14,7 %	3,0 %
Likviditetsgrad	213,8 %	290,7 %	374,5 %	103,1 %

Resultat

29.06.2023

Gæld

29.06.2023

Årsrapport

29.06.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 29.06.2023)

Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of a few provisions for reporting class C. The accounting policies applied to these financial statements are consistent with those applied last year.

Oplysning om pantsætninger og sikkerhedsstillelser:13 Assets charged and collateralThe Company does not have pledges or collaterals.

Oplysning om eventualaktiver:11 Contingent assetsThe Company has deferred tax at a carrying amount of DKK 4. 157k at 22% corporation income tax rate. As it is uncertain if this deferred tax assets can be utilised within a foreseeable future (3-5 years), the carrying amount has not been recognised in the financial statements.

Beretning

29.06.2023

Dato for ledelsens godkendelse af årsrapporten:2023-06-12

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today considered and approved the annual report of Zerion Pharma A/S for the financial year 01. 01. 2022 - 31. 12. 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesZerion Pharma (“Zerion” or “the Company”) is a drug development company, which has developed a new formulation technology, Dispersome®, that enables poorly soluble drugs to become effective pharmaceutical products. The Company was established in January 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion is focused on 1) improving existing drug products, thereby building a pipeline and on 2) partnering with major pharmaceutical and biotech companies to solve their problems with solubility and bioavailability in new pharmaceutical products. Zerion’s R&D activities comprise firstly in house lab work to develop formulations of both new and existing drug candidates. Since inception, the Company’s research labs have been located at the University of Copenhagen where the Company employs 10 scientists and technicians. Secondly, Zerion conducts external R&D activities in the form of pre-clinical and eventually clinical studies with selected drug candidates which incorporate the Dispersome® technology.